Rare diseases
Investigational molecules
Locations
215 Church Street, 06510-1803, United States
Biohaven Therapeutics Ltd. funds clinical research in refractory focal onset epilepsy and idiopathic generalized epilepsy with generalized tonic-clonic seizures, with attention to seizure control, treatment response, and overall safety in adults living with difficult-to-manage epileptic conditions.
The sponsor’s epilepsy portfolio reflects interest in therapies aimed at reducing seizure burden and addressing unmet needs in chronic neurological disorders.
Biohaven Therapeutics Ltd. runs clinical trials in conditions such as Partial seizures, Parkinson's disease, Idiopathic generalised epilepsy, among others.
Clinical trials run by this sponsor – those enrolling participants first.
Study on the Safety of BHV-7000 for Adults with Hard-to-Treat Focal Onset Epilepsy
AustriaA study to test if BHV-8000 is effective and safe for adults with early Parkinson's disease
AustriaStudy on the Effectiveness and Safety of BHV-7000 for Adults with Refractory Focal Onset Epilepsy
AustriaStudy on BHV-7000 for Patients with Generalized Tonic-clonic Seizures in Idiopathic Generalized Epilepsy
AustriaStudy on the Effectiveness and Safety of BHV-7000 for Adults with Refractory Focal Onset Epilepsy
DenmarkIncrease visibility for your trials and help patients find your site through our platform.
Tell us about your condition – we search every trial in Europe and connect you with the right site.
